We report a prostate cancer genome-wide association follow-on study. We discovered four variants associated with susceptibility to prostate cancer in several European populations: rs10934853 [ ) . In a multivariate analysis using 22 prostate cancer risk variants typed in the Icelandic population, we estimated that carriers in the top 1.3% of the risk distribution are at a 2.5 times greater risk of developing the disease than members of the general population.
We and others have previously reported results from genome-wide association studies (GWAS) on prostate cancer that include several common variants associated with disease susceptibility [1] [2] [3] [4] [5] [6] [7] . By scrutinizing our Icelandic GWAS data and publicly available data as well as through examination of fine-mapping work on two previously published loci on 8q24.21 and 11q13, we identified four new variants conferring risk of prostate cancer and a variant refining the previously published association signal on 11q13.
In order to search for prostate cancer risk variants, we analyzed the combined data from the Icelandic GWAS generated using the Illumina 317K chip and from the replication genotyping project released in spring 2008 by the US National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) project using 25,000 SNPs genotyped on five study populations: the Prostate, Lung, Colon and Ovarian Trial (PLCO), the American Cancer Society Prevention Study II (ACS), the Health Professionals Follow-up Study (HPFS), the French Prostate Case-Control Study (FPCC) and the AlphaTocopherol, Beta-Carotene Prevention Study (ATBC) 5, 7 . In the combined study, when we excluded regions containing previously reported prostate cancer risk variants, only two SNPs have P < 1 × 10 −5 . These two newly identified variants are allele A of rs10934853 (rs10934853 [A] ) located on 3q21.3 (a fully correlated marker used from the CGEMS data is rs4857841 with D′ and r 2 = 1 according to Utah CEPH (CEU) HapMap data; Supplementary Table 1) with an allelic odds ratio (OR) of 1.14 and P = 1.6 × 10 −7 and allele C of rs8102476 (rs8102476[C]) located on 19q13.2 with an OR of 1.11 and Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility P = 2.6 × 10 −6 . In the combined study of the Icelandic and CGEMS data, when we analyzed variants located within 1-Mb regions of previously published prostate cancer risk loci, we found only rs445114, located on 8q24.21, to be associated with prostate cancer (OR = 1.14, P = 3.1 × 10 −8 ); this SNP is not correlated with other signals at any of the previously reported prostate cancer loci.
As a part of an ongoing fine-mapping project on the three previously published variants on 8q24.21, we resequenced a 527-kb candidate region on 8q24 using pools of samples from affected (case) and control individuals of Icelandic origin (see Online Methods). We prioritized the analysis of seven SNPs producing suggestive association results for prostate cancer in the analysis of the pooled samples (Supplementary Table 1 ). These seven SNPs were genotyped using a Centaurus (Nanogen) single-track assay in our Icelandic set of up to 1,980 patients and 7,000 controls. Six of these SNPs were found to be correlated with one of the previously reported variants on 8q24, whereas rs16902094 was found not to be correlated with any of the previously reported prostate cancer variants on 8q24.21 ( Supplementary  Tables 1 and 2) . Furthermore, rs16902094 was found to be associated with prostate cancer in the Icelandic study group with an OR of 1.28 (P = 3.5 × 10 −6 ; Tables 1-4). rs16902094 is not present on the Illumina Hap317K chip, and no data are available for it in the HapMap project according to HapMap's official website. However, by genotyping SNPs that are located within the same linkage disequilibrium (LD) region as rs16902094 and are present on the Illumina Hap550 chip, we identified a highly correlated SNP (rs16902104, D′ = 0.98, r 2 = 0.96 according to data from 2,633 Icelanders; Supplementary Table 1) for which CGEMS has released data. By combining the Icelandic data for rs16902094 and the CGEMS data for rs16902104, we obtained an OR of 1.21 (P = 1.1 × 10 −9 ).
The two newly identified SNPs on 8q24.21, rs16902094 and rs445114, are located in the same LD region, but the correlation between them is very low (D′ = 1 and r 2 = 0.07 according to data from 5,450 Icelanders; Supplementary Table 1) and the association for each SNP remains significant after adjustment for the other (Supplementary Table 3a) . This suggests that a unique variant capturing the effect of both rs16902094 and rs445114 remains to be discovered or, alternatively, that the LD region contains more than one variant that predisposes to prostate cancer. Of the previously published cancer variants on 8q24, only the breast cancer variant (rs13281615) 8 is located within the same LD region as the two newly identified 8q24 SNPs; rs445114 is somewhat correlated with the breast cancer variant (D′ = 0.76, r 2 = 0.44; Supplementary Table 2 ), but rs16902094 is much less so (D′ = 0.61, r 2 = 0.06; Supplementary Table 2) . However, both rs16902094 and rs445114 show very little correlation with any of the previously published prostate 1,2,7,9 , colon [10] [11] [12] or bladder cancer 13 risk variants on 8q24 (D′ ≤ 0.6 and r 2 ≤ 0.13; Supplementary Table 2 and Supplementary Fig. 1 ). The results in Iceland for rs16902094, rs445114 and each of the three previously published prostate cancer risk variants on 8q24 remain significant after adjustment for the others (Supplementary Table 3b ). This adds rs16902094 and rs445114 to the list of variants at 8q24 associated with prostate cancer risk. The five 8q24 variants conferring risk of prostate cancer are distributed across four LD regions spanning ~480 kb. One of the five prostate cancer risk variants, rs6983267, has been shown to also affect the risk of colorectal cancer. Other cancer risk variants on 8q24.21 that confer risk of breast or bladder cancer have not been shown to predispose to prostate cancer 13, 14 .
We proceeded to genotype the four newly discovered SNPs (rs10934853 on 3q21.3, rs8102476 on 19q13.2, and rs16902094 and rs16902104 on 8q24.21) in at least two out of five prostate cancer deCODE follow-up groups of European descent. These groups come from The Netherlands, Spain, Finland and the United States (see Supplementary Note). When the results for successfully genotyped SNPs in these groups were combined with the Icelandic and CGEMS data discussed above, they were significant for all loci, surpassing a commonly used genome-wide significance threshold of P ≤ 10 −7 . In examining the literature, we found that Duggan et al. 15 had published an association for rs10934853 (OR = 1.21, P = 0.045) on 3q21.3 from a study on aggressive prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study population. This adds further significance to the combined analysis of the 3q21.3 locus (see Tables 1-4 for combined OR and P values for all four loci).
A test of heterogeneity in the OR for all variants and all study groups showed a nominally significant heterogeneity (P het = 0.039) for the 3q21.3 locus, and no significant difference was observed for the other three loci (P het > 0.1). For rs10934853 on 3q21.3, the estimated OR was greater for the combined US study groups (OR = 1.21, 95% CI = 1.13-1.28) than for the combined European study groups (OR = 1.08, 95% CI = 1.04-1.13). This observation, although noteworthy, needs further confirmation.
A prostate cancer risk variant located on 11q13 with an allelic frequency of ~0.5 was reported previously by two groups independently. Thomas et al. 5 reported rs10896449 and Eeles et al. 4 reported rs7931342 (the two SNPs are highly correlated with D′ = 1 and r 2 = 0.97 according to CEU, HapMap data). In the Icelandic All P values shown are two-sided. Shown are the corresponding numbers of cases and controls (n), allelic frequencies of variants in affected and control individuals, the allelic odds ratio (OR) with 95% confidence interval (95% CI) and the P value. Also shown are the P values for the heterogeneity of the ORs (P het ) for all study groups as well as I 2 , which lies between 0% and 100% and describes the proportion of total variation in study estimates that is due to heterogeneity. 15 . d For the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, and the OR and the P value were estimated using the Mantel-Haenszel model.
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volume 41 | number 10 | october 2009 Nature GeNetics l e t t e r s GWAS dataset, the strongest association with prostate cancer on 11q13 was observed for allele G of rs10896450 (OR = 1.13, P = 2.5 × 10 −4 ; A of the refinement SNP rs11228565 was found to confer greater risk of disease than the anchor SNP (rs10896450), with an OR of 1.24 (P = 0.0057) and a control frequency of 0.177 in the Icelandic study group (Table 4 and Supplementary Table 4) . We then tested the two SNPs rs10896450 and rs11228565 in the five deCODE follow-up groups. For the Finnish study group, instead of genotyping rs10896450, we used data available for a previously reported highly correlated SNP rs7931342 (D′ = 1; r 2 > 0.97 according to CEU HapMap data) previously reported by Kote-Jarai et al. 16 . Combining the results from Iceland and the deCODE follow-up groups gave an estimated OR of 1.15 (P = 2.6 × 10 −8 ) for rs10896450 [G] , whereas for rs11228565[A] the OR was estimated to be 1.23 (P = 6.7 × 10 −12 ) ( Table 4 and Supplementary Table 5 ). The estimated frequency of the risk allele of rs11228565 in the combined dataset containing the groups used in this study was 0.20, compared to 0.50 for the G allele a Results presented for Iceland were adjusted for relatedness (see Online Methods). b For the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, and the OR and the P value were estimated using the Mantel-Haenszel model. l e t t e r s Table 5 ). Hence, the frequency of the risk allele for the newly discovered SNP was lower than for the previously reported SNP. Also, the point estimate of the OR for the newly discovered SNP was greater than that for the previously reported SNP (OR = 1.23 for rs11228565 versus 1.15 for rs10896450), although the difference between the two ORs is not significant (P = 0.08 using results for all study groups; Supplementary Table 5) .
The estimated association effect (OR) for rs11228565 was strongest for the study groups from Nashville, Tennessee, USA and from Finland but weakest for the Spanish group. However, a test of heterogeneity in the OR of all study groups showed no significant difference for the 11q13 locus (P = 0. Table 5 ).
For the six study groups of European descent (excluding the five CGEMS groups and the study by Duggan et al. 15 ) for which we had information about age at diagnosis, no age effect was seen for any of the five loci discussed above (P ≥ 0.3). By computing the genotypespecific ORs or by inspecting the genotypic ORs from the public CGEMS dataset for the variants in Tables 1-4 , we found that the multiplicative model provides an adequate fit for all five loci in the study groups analyzed (for the full as compared to the multiplicative model all P > 0.1; Supplementary Highly correlated markers are shown in parentheses as well as the study reporting them. All P values are two-sided. Shown are the corresponding numbers of cases and controls (n), allelic frequencies of variants in affected and control individuals, the allelic odds ratio (OR) with 95% confidence interval (95% CI) and P value adjusted for relatedness. b The original results published for the loci on 9q33 15 and 22q13 19 were from a study on individuals with aggressive prostate cancer. Results for these two loci in Icelandic cases (n = 693) with more aggressive prostate cancer (Gleason score > 6 and/or stage T3 or higher and/or node-positive cancer and/or metastatic disease) using the same set of controls were not significant (rs1571801, OR aggr = 0.90 and P = 0.080; rs9623117, OR aggr = 1.00 and P = 0.94). c The SNP marker, rs4962416, at the 10q26 locus is not on the Illumina Hap300 chip; results shown for it are based on a weighted combination of two marker haplotype generated from rs7077275 and rs893856 that are present on the chip and tag the SNP (rs4962416). a Results presented for Iceland were adjusted for relatedness (see Online Methods). b For the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, and the OR and the P value were estimated using the Mantel-Haenszel model.
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volume 41 | number 10 | october 2009 Nature GeNetics l e t t e r s 0.94 and 1.03 (P > 0.1) was observed for the five loci. The public CGEMS data also showed no difference between individuals with more aggressive compared with less aggressive disease (P > 0.40) for the SNPs where data are available (3q21, 8q24 and 19q13.2). The study published by Duggan et al. 15 was on aggressive prostate cancer only, and a comparison with less aggressive disease was therefore not possible. The four newly discovered loci reported here add to the rapidly growing number of prostate cancer susceptibility variants identified through GWAS. In Table 5 , we provide results from the Icelandic GWAS for risk variants reported by us and others (with a cutoff date of February 2009) to confer risk of prostate cancer. For some of the SNP associations reported in other populations, the Icelandic results provide replication (in particular, 7p15 and 10q11), although we failed to replicate association for other SNPs in this population (in particular, 9q33 and 22q13). In order to summarize the overall effect of the variants in Tables 1-5 , we combined the effect of all variants affecting risk of prostate cancer in the Icelandic population. We performed a multivariate analysis using a multiplicative model for 22 risk variants. We found no significant deviation from the multiplicative model observed for any variant and no interaction between variants (see Online Methods). Based on this analysis, we estimate the risk of disease is over 2.5 times greater for the top 1.3% of the risk distribution, using the population average risk as a reference (Table 6) . Similarly, the risk of disease is over three times greater for the top 0.3% of the risk distribution. For the 1.3% of individuals, this corresponds to a lifetime risk of over 30% of being diagnosed with prostate cancer compared with a risk of 12% on average in Iceland of getting the disease before age 75 according to NORDCAN (see URL below) and assuming no interaction between the effect of the variants and age at diagnosis. The combined risk estimates presented here are similar to those previously reported by Kote-Jarai et al. for 15 risk variants 16 . We note that the estimates provided here are based solely on our Icelandic study population and that more accurate estimates could be obtained from large prospective studies. Also, given the fast pace of discoveries in the current era of GWAS, additional variants associated with prostate cancer risk are likely to be discovered, suggesting the need for constant updating of such multivariate risk models.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website. Results from a multivariate risk model analysis for prostate cancer in Iceland based on susceptibility variants in table 1-5. Results from Iceland were used for all variants in tables 1-5 except for rs1571801 on 9q33, because its effect was in the opposite direction, and rs10896450 on 11q13, for which data for the refinement SNP in table 4 was used. Odds ratios (OR) were calculated for all possible genotype combinations based on 22 variants and expressed relative to the average general population risk assuming the multiplicative model between variants. The combined OR estimates were then divided into OR ranges and presented along with the percentage of the population within each OR range. The general population risk was determined using a frequency-weighted average risk for all possible genotypes.
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Genotyping methods. Illumina genotyping. 1,968 Icelandic case and 35,382
Icelandic control samples were successfully assayed with the Infinium HumanHap300 SNP chip (Illumina) containing 317,503 haplotype tagging SNPs derived from phase I of the International HapMap project. Of the SNPs assayed on the chip, 2,906 SNPs had a yield <95%, and 271 SNPs had a minor allele frequency (in the combined set of cases and controls) <0.01 or were monomorphic. An additional 4,632 SNPs showed a significant distortion from Hardy-Weinberg equilibrium in the controls (P < 1.0 × 10 −3 ). In total, 6,983 unique SNPs were removed from the study. Thus, the analysis reported in the main text uses 310,520 SNPs. Any samples with a call rate below 98% were excluded from the analysis. Replication genotyping. Single SNP genotyping of the SNPs reported in the main text for the case-control groups from Iceland, The Netherlands, Spain and Chicago was carried out by deCODE Genetics in Reykjavik, Iceland, applying the Centaurus 20 platform. The quality of each Centaurus SNP assay was evaluated by genotyping each assay in the CEU and/or YRI HapMap samples and comparing the results with the HapMap publicly released data. Assays with >1.5% mismatch rate were not used, and an LD test was used for markers known to be in LD. We regenotyped >10% of the samples and observed a mismatch rate <0.5%. Genotyping of samples from Finland and from Nashville, Tennessee, USA, was done using the same Centaurus assays as was used in Iceland at the University of Tampere and Vanderbilt University, respectively, using standard protocols.
For each of the SNPs discussed in the main text, the yield was >95% for those samples for which genotyping was attempted in all study groups.
The SNPs rs16902094 on 8q24 and rs11228565 on 11q13 are not present on the HumanHap300 chip. Therefore, using a single SNP assay for genotyping, an attempt was made to genotype 6,900 and 800 individuals, respectively, of the 35,382 Icelandic controls as well as 1,860 Icelandic cases and all available individuals from the replication study groups.
Discovery of a previously unidentified SNP on 8q24 by Solexa resequencing. In order to search for new SNPs on 8q24, a 527-kb region (128,113, 108-128,640,337 bp, Build 36) was sequenced using the Solexa resequencing platform (Illumina Inc.). From our set of ~2,000 cases, 800 were selected randomly and split into two DNA pools, each with 400 samples. Similarly, 800 control individuals not known to have prostate cancer were selected randomly and split into two DNA pools with 400 samples each. Dilutions were prepared in duplicates for the four pools and used for long-range PCR reactions (each amplimer consisted of ~10 kb). PCR fragments were run on 0.8% agarose gels, the DNA was visualized with BlueView (Sigma Inc.) under normal light and the sizes of the PCR fragments were estimated with HindIII-digested lambda size marker (Fermentas Inc). Bands of correct sizes were excised out of the agarose gels and purified with Qiagen gel extraction kit (Qiagen Inc.). The PCR products were quantified by PicoGreen assay (Invitrogen Inc.) as described by the manufacturer. The preparation of the Solexa DNA libraries, the cluster generation and the DNA sequencing was done according to a published procedure 21 . The SNP analysis pipeline is composed of four components: alignment, SNP calling, filtering and association analysis. Promising SNPs were selected for further study and confirmation using Centaurus single-track SNP assays.
Statistical analysis. Association analysis. For SNPs that were in strong LD, whenever the genotype of one SNP was missing for an individual, the genotype of the correlated SNP was used to provide partial information through a likelihood approach as previously described 9 . This ensured that results presented in Supplementary Table 5 were based on the same number of individuals and allowed meaningful comparisons of results for correlated SNPs. A likelihood procedure described in a previous publication 22 and implemented in the NEMO software (deCODE) was used for the association analyses.
We tested the association of an allele to prostate cancer using a standard likelihood ratio statistic that, if the subjects were unrelated, would have asymptotically a χ 2 distribution with 1 degree of freedom under the null hypothesis. Allelic frequencies rather than carrier frequencies are presented for the markers in the main text. Allele-specific ORs and associated P values were calculated assuming a multiplicative model for the two chromosomes of each individual 23 . Results from multiple case-control groups were combined using a Mantel-Haenszel model 24 in which the groups were allowed to have different population frequencies for alleles, haplotypes and genotypes but were assumed to have common relative risks (see ref. 3 for a more detailed description of the association analysis).
The control groups from Iceland, The Netherlands, Spain and Finland included both male and female controls. No significant difference between male and female controls was detected for SNPs presented in Tables 1-4 for each of these four groups. Controls from other study groups included only males.
In order to assess the association for the SNP rs4962416 on 10q26, which is in the CEU section of the HapMap database but is absent from the Illumina HumanHap300 chip, we used a method based on haplotypes of two markers (rs7077275 and rs893856) present on the chip. We used a method we have previously employed 25 that is an extension of the two-marker haplotype tagging method 26 and is similar in spirit to two other proposed methods 27, 28 . We computed associations with a linear combination of the haplotypes chosen to act as surrogates to HapMap markers in the regions. These calculations were based on 1,724 prostate cancer cases and 35,322 controls genotyped on the HumanHap300 chip.
Multivariate analysis. In a multivariate analysis, we combined the effects of 22 variants associated with risk of prostate cancer using estimates based on data from only the Icelandic study group. A multiplicative model was assumed at each variant and between all variants. For the 21 autosomal variants, we tested for deviation from the multiplicative model when comparing it to the full model of genotypic OR. Given the number of tests performed, no significant deviation from the multiplicative model was detected (all P > 0.0024, corresponding to P = 0.05 divided by 21). For the variant located on the X chromosome (rs5945572), there exist only two male genotypes (carrier and noncarrier). Also, we tested the pairwise interactions between the 22 risk variants using logistic regressions including terms corresponding to the 231 possible pairs. Given the number of tests performed, no significant deviation from the multiplicative model was detected with a level of significance <0.00022 (corresponding to P = 0.05 divided by 231). Similarly, the absence of interaction between variants has previously been reported 5, 16, 29 . Odds ratios were calculated for all possible genotype combinations based on these 22 variants and expressed relative to the average general population risk. The combined OR estimates were then divided into OR ranges and presented along with the percentage of the population within each OR range ( Table 6 ). The general population risk was determined using a frequency-weighted average risk for all possible genotypes.
The Icelandic samples were part of the initial discovery study populations for 10 of these 22 variants, and therefore the estimates for these variants may be inflated due to winner's curse (whereby marginally significant association produces inflated effect due to the fact that their only chance to be significant is to have those estimates inflated). From Tables 1-4, we are using the estimates for the following variants: rs10934853 on 3q21.3, rs11228565 on 11q13 and rs8102476 on 19q13.2. For the five variants (rs1447295, rs6983267, rs16901979, rs16902094 and rs445114) on 8q24.21, we are using the adjusted estimates as reported in Supplementary Table 3b . From Table 5 , we use the estimates for all variants except rs1571801 on 9q33 because its effect was in the opposite direction compared to the original publication and rs10896450 on 11q13 for which data for the refinement SNP (rs11228565) in Tables 1-4 was used. Furthermore, for the two variants on 17q12, reported in Table 5 , we are using the estimates adjusted for each other because the two markers are located ~25 kb from each other but are not correlated (D′ = 0.03, r 2 = 0.0004 according to CEU HapMap data); rs4430796 has an adjusted OR of 1.17 (95% CI: 1.08-1.26) and rs11649743 has an adjusted OR of 1.06 (95% CI: 0.99-1.14).
We applied the combined genetic relative risk to the lifetime risk by multiplying them together. Because the association with disease for these variants has not been shown to depend on age at diagnosis 3, 16 , we assumed that the individual estimates for each variant will have a similar effect at any given age. The lifetime risk of getting prostate cancer is estimated to be 12% on average in Iceland before the age of 75, according to Cancer Incidence, Mortality and Prevalence in the Nordic Countries (NORDCAN) (see URL section).
Analysis of the CGEMS data. For the five individual study populations from the CGEMS study 5, 7 (ACS, American Cancer Society Prevention Study
